Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Search Results

Display Settings
Results per page: 10
Sort By: Relevance
Filter
  • 1-10 of  776 results for ""F.""

Your Filters

Publication : bmc cancer Subject : antineoplastic combined chemotherapy protocols Subject : oncology Filter by : Author
Reset filters
Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Academic Journal

heredERA Breast Cancer: a phase III, randomized, open-label study evaluating the efficacy and safety of giredestrant plus the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with previously untreated HER2-positive, estrogen receptor-positive locally advanced or metastatic breast cancer.

  • Authors : Kuemmel S; Breast Unit, Kliniken Essen Mitte, Essen, Germany.; Department of Gynecology with Breast Center, Charité - Universitätsmedizin Berlin, Berlin, Germany.

Subjects: Breast Neoplasms*/Breast Neoplasms*/Breast Neoplasms*/drug therapy ; Breast Neoplasms*/Breast Neoplasms*/Breast Neoplasms*/pathology ; Breast Neoplasms*/Breast Neoplasms*/Breast Neoplasms*/genetics

  • Source: BMC cancer [BMC Cancer] 2024 May 24; Vol. 24 (1), pp. 641. Date of Electronic Publication: 2024 May 24.Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407

Record details

Read Online Read More Add to Saved list
×
Academic Journal

TALASUR trial: a single arm phase II trial assessing efficacy and safety of TALazoparib and Avelumab as maintenance therapy in platinum-Sensitive metastatic or locally advanced URothelial carcinoma.

  • Authors : Coquan E; Medical Oncology Department, Centre François Baclesse, 3 Avenue du Général Harris, 14076, Caen Cedex 05, France. .; Clinical Research Department Centre François Baclesse, 14076, Caen, France. .

Subjects: Carcinoma, Transitional Cell*/Carcinoma, Transitional Cell*/Carcinoma, Transitional Cell*/drug therapy ; Carcinoma, Transitional Cell*/Carcinoma, Transitional Cell*/Carcinoma, Transitional Cell*/pathology ; Urinary Bladder Neoplasms*/Urinary Bladder Neoplasms*/Urinary Bladder Neoplasms*/drug therapy

  • Source: BMC cancer [BMC Cancer] 2022 Nov 24; Vol. 22 (1), pp. 1213. Date of Electronic Publication: 2022 Nov 24.Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407

Record details

Read Online Read More Add to Saved list
×
Academic Journal

Rationale and design of a phase II trial of pyrotinib in combination with nab-paclitaxel as adjuvant therapy for N0/N1mi, HER2 + early breast cancer (PHAEDRA).

  • Authors : Wang C; Department of Breast Surgery, Peking Union Medical College Hospital, No.41 DaMuCang Lane, Xicheng District, Beijing, 100032, China.; Zhou Y

Subjects: Acrylamides*/Acrylamides*/Acrylamides*/administration & dosage ; Acrylamides*/Acrylamides*/Acrylamides*/adverse effects ; Albumins*/Albumins*/Albumins*/administration & dosage

  • Source: BMC cancer [BMC Cancer] 2022 Mar 14; Vol. 22 (1), pp. 269. Date of Electronic Publication: 2022 Mar 14.Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407

Record details

Read Online Read More Add to Saved list
×
Academic Journal

Additional capecitabine use in early-stage triple negative breast cancer patients receiving standard chemotherapy: a new era? A meta-analysis of randomized controlled trials.

  • Authors : Ye F; Department of Breast Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, 651 East Dongfeng Road, Guangzhou, Guangzhou, 510060, Guangdong, China.; Bian L

Subjects: Antimetabolites, Antineoplastic/Antimetabolites, Antineoplastic/Antimetabolites, Antineoplastic/*therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/Antineoplastic Combined Chemotherapy Protocols/Antineoplastic Combined Chemotherapy Protocols/*therapeutic use ; Capecitabine/Capecitabine/Capecitabine/*therapeutic use

  • Source: BMC cancer [BMC Cancer] 2022 Mar 12; Vol. 22 (1), pp. 261. Date of Electronic Publication: 2022 Mar 12.Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407

Record details

Read Online Read More Add to Saved list
×
Academic Journal

Safety and efficacy of MIKE-1 in patients with advanced pancreatic cancer: a study protocol for an open-label phase I/II investigator-initiated clinical trial based on a drug repositioning approach that reprograms the tumour stroma.

  • Authors : Mizutani Y; Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, Nagoya, Japan.; Department of Pathology, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Subjects: Albumins/Albumins/Albumins/*administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/Antineoplastic Combined Chemotherapy Protocols/Antineoplastic Combined Chemotherapy Protocols/*administration & dosage ; Benzoates/Benzoates/Benzoates/*administration & dosage

  • Source: BMC cancer [BMC Cancer] 2022 Feb 24; Vol. 22 (1), pp. 205. Date of Electronic Publication: 2022 Feb 24.Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407

Record details

Read Online Read More Add to Saved list
×
Academic Journal

Randomized double-blind clinical trial comparing safety and efficacy of the biosimilar BCD-021 with reference bevacizumab.

Subjects: Antineoplastic Combined Chemotherapy Protocols/Antineoplastic Combined Chemotherapy Protocols/Antineoplastic Combined Chemotherapy Protocols/*adverse effects ; Bevacizumab/Bevacizumab/Bevacizumab/*adverse effects ; Biosimilar Pharmaceuticals/Biosimilar Pharmaceuticals/Biosimilar Pharmaceuticals/*adverse effects

  • Source: BMC cancer [BMC Cancer] 2022 Feb 01; Vol. 22 (1), pp. 129. Date of Electronic Publication: 2022 Feb 01.Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407

Record details

Read Online Read More Add to Saved list
×
Academic Journal

Trastuzumab and fulvestrant combination therapy for women with advanced breast cancer positive for hormone receptor and human epidermal growth factor receptor 2: a retrospective single-center study.

  • Authors : Ozaki Y; Breast Oncology Center, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo, 135-8550, Japan. .; Department of Clinical Oncology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan. .

Subjects: Antineoplastic Combined Chemotherapy Protocols/Antineoplastic Combined Chemotherapy Protocols/Antineoplastic Combined Chemotherapy Protocols/*administration & dosage ; Breast Neoplasms/Breast Neoplasms/Breast Neoplasms/*drug therapy ; Fulvestrant/Fulvestrant/Fulvestrant/*administration & dosage

  • Source: BMC cancer [BMC Cancer] 2022 Jan 04; Vol. 22 (1), pp. 36. Date of Electronic Publication: 2022 Jan 04.Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407

Record details

Read Online Read More Add to Saved list
×
Academic Journal

Prognostic nomogram for patients with unresectable pancreatic cancer treated with gemcitabine plus nab-paclitaxel or FOLFIRINOX: A post-hoc analysis of a multicenter retrospective study in Japan (NAPOLEON study).

  • Authors : Shibuki T; Department of Internal Medicine, Imari Arita Kyoritsu Hospital, 860 Ninose-ko, Arita-cho, Nishi-matsuura-gun, Saga, 849-4193, Japan.; Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa-shi, Chiba, 277-8577, Japan.

Subjects: Nomograms*; Albumins/Albumins/Albumins/*therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/Antineoplastic Combined Chemotherapy Protocols/Antineoplastic Combined Chemotherapy Protocols/*therapeutic use

  • Source: BMC cancer [BMC Cancer] 2022 Jan 03; Vol. 22 (1), pp. 19. Date of Electronic Publication: 2022 Jan 03.Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407

Record details

Read Online Read More Add to Saved list
×
Academic Journal

Study protocol of an open-label, single arm phase II trial investigating the efficacy, safety and quality of life of neoadjuvant chemotherapy with liposomal irinotecan combined with Oxaliplatin and 5-fluorouracil/Folinic acid followed by curative surgical resection in patients with hepatic Oligometastatic adenocarcinoma of the pancreas (HOLIPANC).

  • Authors : Gebauer F; Department of General, Visceral, Tumor and Transplantation Surgery, University of Cologne, Kerpener Strasse 62, 50937, Cologne, Germany. .; Damanakis AI

Subjects: Adenocarcinoma*/Adenocarcinoma*/Adenocarcinoma*/drug therapy ; Adenocarcinoma*/Adenocarcinoma*/Adenocarcinoma*/mortality ; Adenocarcinoma*/Adenocarcinoma*/Adenocarcinoma*/secondary

  • Source: BMC cancer [BMC Cancer] 2021 Nov 18; Vol. 21 (1), pp. 1239. Date of Electronic Publication: 2021 Nov 18.Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407

Record details

Read Online Read More Add to Saved list
×
Academic Journal

Impact of the line of treatment on progression-free survival in patients treated with T-DM1 for metastatic breast cancer.

  • Authors : Migeotte A; Université catholique de Louvain, Brussels, Belgium.; Department of Medical Oncology, King Albert II Cancer Institute, Cliniques universitaires Saint-Luc, Brussels, Belgium.

Subjects: Ado-Trastuzumab Emtansine/Ado-Trastuzumab Emtansine/Ado-Trastuzumab Emtansine/*therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/Antineoplastic Combined Chemotherapy Protocols/Antineoplastic Combined Chemotherapy Protocols/*therapeutic use ; Breast Neoplasms/Breast Neoplasms/Breast Neoplasms/*drug therapy

  • Source: BMC cancer [BMC Cancer] 2021 Nov 11; Vol. 21 (1), pp. 1204. Date of Electronic Publication: 2021 Nov 11.Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407

Record details

Read Online Read More Add to Saved list
×
  • 1-10 of  776 results for ""F.""